Search clinical trials for: Placebo to TS-142

Total 1877 results

Taisho Pharmaceutical Co., Ltd.

Completed

Phase III Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Patients With Mild Obstructive Sleep Apnea Hypopnea

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Insomnia Disorder

Japan
Taisho Pharmaceutical R&D Inc.

Completed

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Healthy Volunteer

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Healthy Volunteer

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

Healthy Volunteer

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Late Phase II Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)

Healthy Participants

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

Healthy Participants

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Healthy Adult Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Food Effect Study of TS-142 in Healthy Subjects

Effect of Food

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Chronic Kidney Disease

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Taisho Pharmaceutical R&D Inc.

Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

Narcolepsy

Japan, Korea, Republic of
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Healthy Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

Healthy Subjects

Japan
Vantia Ltd

Completed

VA111913 TS: First in Human Study

Dysmenorrhea

United Kingdom
Vantia Ltd

Completed

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

Primary Dysmenorrhea

United States, United Kingdom
Taisho Pharmaceutical R&D Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Major Depressive Disorder

United States
SecuraBio

Completed

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus Erythematosus

Greece, Germany, Italy
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Taisho Pharmaceutical R&D Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Healthy Volunteers

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

Healthy Subjects

Japan
Taisho Pharmaceutical R&D Inc.

Completed

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Healthy Volunteers

United States
Gilead Sciences

Recruiting

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (SWIFT)

Ulcerative Colitis

United States
National Institute of Mental Health (NIMH)
Taisho Pharmaceutical Co., Ltd.

Recruiting

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

Depression | Major Depressive Disorder | Treatment-Resistant Depression

United States
University Hospital, Toulouse

Completed

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years (Oxyjeune)

Prader-Willi Syndrome

France
Amgen

Completed

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Post Menopausal Osteoporosis

Canada, Denmark, United States, Belgium, Poland, Spain, Australia
Boehringer Ingelheim

Completed

Monotherapy Dose Finding With BI 847325 in Solid Tumours

Neoplasms

Belgium
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
Daewoong Pharmaceutical Co. LTD.
Shanghai Haini Pharmaceutical Co., Ltd.

Active, not recruiting

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

Phase 1 Study, Healthy Volunteers

China
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Healthy Volunteers

United States
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Amgen
Daiichi Sankyo, Inc.

Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Cancer | Multiple Myeloma | Bone Metastases | Hematologic Malignancies | Oncology | Multiple Myeloma Bone Lesions

United States, Germany, Italy, Spain, Canada, France, Czechia, Hungary, Korea, Republic of, Russian Federation, United Kingdom, Taiwan, Australia, Hong Kong, New Zealand, Austria, Slovakia, Portugal, Greece, Bulgaria, Poland, Ukraine and more
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Hospices Civils de Lyon

Completed

Cochlear Implants : Influence of Microphone Aging and Dirtying

Hard of Hearing

France
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa

Search clinical trials for: Placebo to TS-142

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations